Illustrative image – not actual.Dr. Reddy’s Laboratories Ltd (DRL) is setting up
biotech production facilities conforming to US FDA specifications. The project
includes setting up of three class-10,000 bulk recombinant protein production
suites and a new formulations facility. DRL has already invested Rs.10 crore in
this project.
DRL’s biotech business focuses on molecular biology,
cell culture, fermentation, downstream, processing and hybridoma technology.
The company has already launched Grastim, which serves as an
import-substitute cancer therapy drug.
